Puma Biotechnology, Inc. (NASDAQ: PBYI) is a Healthcare company (Biotechnology) with a market capitalization of $362M. The Maz Rating grades it against the other companies in its sector.
Puma Biotechnology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.01, Puma Biotechnology, Inc. trades at 15.4x trailing earnings, 1.6x sales and 2.6x book value, with an EV/EBITDA of 8.5. Over the last twelve months it generated about $221M of revenue and $24M of net income. It runs a gross margin of 73.6%, an operating margin of 11.3% and a net margin of 10.3%. It shows return on equity of 17.5%, return on invested capital of 14.6% and a free cash flow yield of 12.1%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 3.03. Over the past 52 weeks the share price ranged from $3.03 to $11.50, with a beta of 1.21.
Puma Biotechnology, Inc. does not currently pay a dividend.
20 Wall Street analyst ratings cover the stock: 8 Buy, 8 Hold and 4 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.